Abstract

77P A single-arm trial of BACE plus tislelizumab in patients with NSCLC: Updated analysis

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
74P The safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients (pts) with locally recurrent or metastatic triple-negative breast cancer (TNBC): A multi-cohort, phase II trial
W Zhang ... Z Wang
Immuno-Oncology and Technology | VOL. 16
W Zhang, et. al.W Zhang ... Z Wang
01 Dec 2022
Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer.
Ang Li ... Jiale Gao
Frontiers in oncology | VOL. 13
Ang Li, et. al.Ang Li ... Jiale Gao
02 Feb 2023
Outcome of patients with recurrent/refractory osteosarcoma enrolled in three recent phase II trials: A report from the Children’s Oncology Group.
Pooja Hingorani ... Seema Rao
Journal of Clinical Oncology | VOL. 39
Pooja Hingorani, et. al.Pooja Hingorani ... Seema Rao
20 May 2021
Matching-Adjusted Indirect Comparisons of Efficacy Outcomes in Patients with Relapsed and Refractory Multiple Myeloma for Idecabtagene Vicleucel (KarMMa) Versus Selinexor Plus Dexamethasone (STORM Part 2) and Belantamab Mafodontin (DREAMM-2): Updated Analysis with Longer Follow-up
Clyde Caisip ... Paula Rodríguez-Otero
Blood | VOL. 138
Clyde Caisip, et. al.Clyde Caisip ... Paula Rodríguez-Otero
05 Nov 2021
View more papers

More From: Immuno-Oncology and Technology

Paper Title
Journal
Date
Author
Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy – a retrospective and biomarker study
Fernanda Costa Svedman ... Suzanne Egyhazi Brage
Immuno-Oncology and Technology | VOL. -
Fernanda Costa Svedman, et. al.Fernanda Costa Svedman ... Suzanne Egyhazi Brage
01 May 2024
Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial
Caroline Dive ... Kirellos S Abbas
Immuno-Oncology and Technology | VOL. 22
Caroline Dive, et. al.Caroline Dive ... Kirellos S Abbas
18 Mar 2024
Table of Contents
-
Immuno-Oncology and Technology | VOL. 21
--
01 Mar 2024
Editorial Board
-
Immuno-Oncology and Technology | VOL. 21
--
01 Mar 2024
View more papers